Cortexyme is a biopharmaceutical company developing therapeutics based on data supporting a new theory of the cause of Alzheimer's and other degenerative disorders. Cortexyme is targeting a specific pathogen tied to neurodegeneration. The target has been validated in a number of animal models and Cortexyme is enrolling patients in a Phase 2/3 clinical trial of its lead small molecule in mild to moderate Alzheimer's disease. Source
No articles found.
Merus is a clinical-stage immuno-oncology company developing innovative full-lengt...
Merus is a clinical-stage immuno-oncology compa...
Chembio is a leading point-of-care diagnostics company focused on detecting and di...
Chembio is a leading point-of-care diagnostics ...
Private Health Management was founded in 2007 after Leslie D. Michelson and Gregg ...
Private Health Management was founded in 2007 a...
Syneos HealthÂŽ (Nasdaq:SYNH) is the only fully integrated biopharmaceutical solut...
Syneos HealthÂŽ (Nasdaq:SYNH) is the only fully...
Regulus Therapeutics Inc. (Nasdaq: RGLS) is a clinical stage biopharmaceutical com...
Regulus Therapeutics Inc. (Nasdaq: RGLS) is a c...
vTv Therapeutics is a clinical-stage biopharmaceutical company engaged in the disc...
vTv Therapeutics is a clinical-stage biopharmac...
WindowMirror's BUTTERFLY will be a collaborative SaaS (Software as a Service) plat...
WindowMirror's BUTTERFLY will be a collaborativ...
Intra-Cellular Therapies is a biopharmaceutical company developing novel drugs, le...
Intra-Cellular Therapies is a biopharmaceutical...
BrainStorm (NASDAQ:BCLI) is a biotechnology company developing innovative, autolog...
BrainStorm (NASDAQ:BCLI) is a biotechnology com...
The mission of Cassava Sciences is to detect and treat neurodegenerative diseases,...
The mission of Cassava Sciences is to detect an...
Join the National Investor Network and get the latest information with your interests in mind.